John Brottem reports Form 144 share sales

John Brottem reported sales of Common Stock via a Form 144 notice.

Rhea-AI Filing Summary

John Brottem reported sales of Common Stock via a Form 144 notice. The filing lists three dispositions: 244 shares on 01/07/2026, 9,314 shares on 01/20/2026, and 1,180 shares on 01/21/2026. The excerpt also shows the settlement of 5,032 vested restricted stock units on 02/15/2026 labeled as equity compensation.

Insights

Securities Compliance Analyst

Routine Form 144 disclosures of insider sales and RSU settlement; no new allegations or material qualifiers.

The filing lists specific disposition dates and share counts: 244 shares on 01/07/2026, 9,314 shares on 01/20/2026, and 1,180 shares on 01/21/2026. It also records the settlement of 5,032 vested RSUs on 02/15/2026 described as equity compensation.

These entries are routine compliance items that notify the market of a selling affiliate's transactions. Timing and cash‑flow treatment are those shown in the excerpt; subsequent filings may provide additional context such as proceeds recipients or trading arrangements.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did John Brottem disclose on Form 144 for OM?

He disclosed three share dispositions and an RSU settlement. The filing lists 244 shares on 01/07/2026, 9,314 shares on 01/20/2026, 1,180 shares on 01/21/2026, and 5,032 vested RSUs settled on 02/15/2026.

Do the Form 144 entries indicate how proceeds were used or who received them?

No, the excerpt does not state proceeds recipients or uses. It records sale dates and share counts; details on cash flow or buyer identities are not provided in the excerpt.

Are the 5,032 units newly issued shares or compensation?

They are described as the settlement of vested restricted stock units on 02/15/2026, and the filing labels this entry as equity compensation for services rendered.

Does the filing show whether these sales were brokered or block trades?

The excerpt does not specify the methods of sale or broker-dealer arrangements. It lists the trades and a brokerage firm name but omits distribution method details.

Is this Form 144 disclosure an indication of wrongdoing or regulatory action?

No; the entries are routine disclosures of insider transactions and an RSU settlement. The filing does not allege or show any misconduct, penalties, or regulatory enforcement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 09:13 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001823381
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Outset Medical, Inc.
SEC File Number	001-39513
Address of Issuer	3052 ORCHARD DRIVE SAN JOSE CALIFORNIA 95134
Phone	669-231-8200
Name of Person for Whose Account the Securities are To Be Sold	Brottem John L.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC 1 New York Plaza 38th Fl. New York NY 10004	2842	9520.70	18311626	02/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/15/2026	Settlement of Vested Restricted Stock Units	Issuer			5032	02/15/2026	Equity compensation for services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
John Brottem 3052 ORCHARD DR. San Jose CA 95134	Common Stock	01/07/2026	244	956.48
John Brottem 3052 Orchard Dr. San Jose CA 95134	Common Stock	01/20/2026	9314	47682.76
John Brottem 3052 Orchard Dr. San Jose CA 95134	Common Stock	01/21/2026	1180	5913.82

144: Remarks and Signature

Remarks	This sale was made to satisfy tax withholding obligations through a sell to cover transaction in connection with the vesting of Restricted Stock Units and does not represent a discretionary trade by the reporting person.
Date of Notice	02/17/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ John L Brottem
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)